Crinetics Pharmaceuticals Inc
CRNX
查看详细走势图
33.670USD
-2.640-7.27%
收盘 03/27, 16:00（美东）报价延迟15分钟
741.01M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
-7.27%
5天
-5.34%
1月
-18.08%
6月
-26.66%
今年开始到现在
-27.67%
1年
-3.05%
查看详细走势图
TradingKey Crinetics Pharmaceuticals Inc股票评分
单位: USD 更新时间: 2026-03-27操作建议
Crinetics Pharmaceuticals Inc当前公司基本面数据相对健康，最新ESG披露属于行业领先水平。增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名39/391位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价83.43。中期看，股价处于下降通道。近一个月，市场表现非常差，但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Crinetics Pharmaceuticals Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
看好
Crinetics Pharmaceuticals Inc亮点
亮点风险
Crinetics Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead development candidate, PALSONIFY (paltusotine), is the first investigational once-daily, oral, selective somatostatin receptor type 2 (SST2) nonpeptide agonist that is in clinical development for acromegaly and carcinoid syndrome associated with neuroendocrine tumors. Its second product candidate is Atumelnant, which is in clinical development for congenital adrenal hyperplasia (CAH) and patients with either Cushing's disease or Ectopic ACTH Syndrome (EAS). Its drug candidates are orally delivered, small molecule new chemical entities resulting from in-house drug discovery efforts, including other programs addressing a variety of endocrine conditions such as hyperparathyroidism, polycystic kidney disease, Graves' disease, thyroid eye disease, diabetes and obesity.
业绩高增长
公司营业收入稳步增长，连续3年增长91.78%
业绩增长期
公司处于发展阶段，最新年度总收入7.70M美元
利润高增长
公司净利润处于行业前列，最新年度总收入7.70M美元
估值高估
公司最新PE估值-6.81，处于3年历史高位
机构加仓
最新机构持股110.25M股，环比增加0.01%
CI 精选加拿大股票基金持仓
明星投资者CI 精选加拿大股票基金持仓，最新持仓市值514.00
活跃度增加
近期活跃度增加，过去20天平均换手率0.06
分析师目标
根据
16
位分析师
买入
评级
83.429
目标均价
+129.77%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Crinetics Pharmaceuticals Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Crinetics Pharmaceuticals Inc简介
Crinetics Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead development candidate, PALSONIFY (paltusotine), is the first investigational once-daily, oral, selective somatostatin receptor type 2 (SST2) nonpeptide agonist that is in clinical development for acromegaly and carcinoid syndrome associated with neuroendocrine tumors. Its second product candidate is Atumelnant, which is in clinical development for congenital adrenal hyperplasia (CAH) and patients with either Cushing's disease or Ectopic ACTH Syndrome (EAS). Its drug candidates are orally delivered, small molecule new chemical entities resulting from in-house drug discovery efforts, including other programs addressing a variety of endocrine conditions such as hyperparathyroidism, polycystic kidney disease, Graves' disease, thyroid eye disease, diabetes and obesity.
公司代码CRNX
公司Crinetics Pharmaceuticals Inc
CEOStruthers (R. Scott)
网址https://www.crinetics.com/
相关品种
